Yuan Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuan Lu has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Jiahua Liu
Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
11 shared publicationsXinjia Du
Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
10 shared publicationsYanfei Ren
Department of Cardiology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
10 shared publicationsLei Chen
Department of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
9 shared publicationsYixuan Wu
Department of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
8 shared publications- Lei Chen
Department of Cardiology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 20 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Association between the peak hs-CRP-based CALLY Index and CMR-derived microvascular obstruction in patients with STEMI after primary PCI
- 20 August 2026
- Published by Springer Nature in European Journal of Medical Research
- Vol. 31 (1)
Open AccessAssociation between the peak hs-CRP-based CALLY Index and CMR-derived microvascular obstruction in patients with STEMI after primary PCI
- 13 August 2026
- Published by Elsevier in Phytomedicine
- Vol. 161, 158718
A novel polysaccharide from Ligusticum chuanxiong attenuates cardiac hypertrophy by targeting ferroptosis through the SIRT3-mediated deacetylation of Foxo3a
- 13 August 2026
- Published by Elsevier in Phytomedicine
- Vol. 161, 158718
A novel polysaccharide from Ligusticum chuanxiong attenuates cardiac hypertrophy by targeting ferroptosis through the SIRT3-mediated deacetylation of Foxo3a
- Open Access
- 16 February 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Predictive value of platelet-to-lymphocyte ratio for new-onset atrial fibrillation after percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
Inflammation represents a key pathophysiological link between acute myocardial infarction and atrial fibrillation. Despite this, the platelet-to-lymphocyte
- 16 February 2026
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessPredictive value of platelet-to-lymphocyte ratio for new-onset atrial fibrillation after percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction
Inflammation represents a key pathophysiological link between acute myocardial infarction and atrial fibrillation. Despite this, the platelet-to-lymphocyte
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1)
Drug–Drug Interaction Signals for Apixaban‐Associated Haemorrhage in Atrial Fibrillation and Thromboembolic Disorders: A Disproportionality Analysis of the FAERS Database
Background: Apixaban is commonly used in anticoagulation therapy. Its safety profile is associated with polypharmacy and potential drug–drug interactions (DDIs). Current understanding often focuses on canonical metabolic pathways, while other biological factors of haemorrhagic risk remain not fully described. Objectives: This study investigated DDI signal drugs associated with haemorrhagic adverse events when apixaban is used with concomitant drugs. The study also explored potential pharmacological mechanisms. Methods: A disproportionality and DDI signal analysis was performed on FDA Adverse Event Reporting System (FAERS) data from the first quarter of 2013 to the first quarter of 2025. DDI signals were identified using six different algorithms. A DDI signal met the analysis criteria if it was detected by all six algorithms including the Ω shrinkage method and the chi‐square test. Concomitant drugs associated with DDI signal drugs were classified using the DrugBank database to investigate pharmacological properties with a focus on metabolic enzymes and transporters. Results: After the exclusion of established interactions, the analysis identified 107 medications and 49 preferred terms. Analysis at the level of enzymes and transporters indicated that noncanonical pathways exhibited risk intensities, including arylsulfatase A (ARSA, weighted mean Ω = 3.60), macrophage metalloelastase (MMP12, weighted mean Ω = 3.16), organic anion transporting polypeptide 2B1 (OATP2B1, weighted mean Ω = 2.82) and bile salt export pump (BSEP, weighted mean Ω = 2.62). DDI signal drugs associated with high‐intensity targets included acyclovir for duodenal ulcer haemorrhage (Ω = 2.90, 95% CI: 2.12–3.69), mesalazine for an increased tendency to bruise (Ω = 2.96, 95% CI: 1.69–4.22) and digitoxin for haematoma (Ω = 2.65, 95% CI: 1.83–3.46). Interaction signals were also recorded for morphine with injection site haematoma (Ω = 3.05, 95% CI: 1.90–4.21) and eltrombopag with internal haemorrhage (Ω = 3.11, 95% CI: 2.04–4.18). Conclusion: Haemorrhagic risks in apixaban therapy are likely associated with a convergence of transport interference, potential impairment of haemostasis and indirect clinical factors, such as medication‐induced instability. These findings suggest that safety management may extend beyond canonical pathways to consider the possible impact of alternative transporters and functional stability. These results provide a preliminary basis for further clinical validation.
- 1 January 2026
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2026 (1)
Open AccessDrug–Drug Interaction Signals for Apixaban‐Associated Haemorrhage in Atrial Fibrillation and Thromboembolic Disorders: A Disproportionality Analysis of the FAERS Database
Background: Apixaban is commonly used in anticoagulation therapy. Its safety profile is associated with polypharmacy and potential drug–drug interactions (DDIs). Current understanding often focuses on canonical metabolic pathways, while other biological factors of haemorrhagic risk remain not fully described. Objectives: This study investigated DDI signal drugs associated with haemorrhagic adverse events when apixaban is used with concomitant drugs. The study also explored potential pharmacological mechanisms. Methods: A disproportionality and DDI signal analysis was performed on FDA Adverse Event Reporting System (FAERS) data from the first quarter of 2013 to the first quarter of 2025. DDI signals were identified using six different algorithms. A DDI signal met the analysis criteria if it was detected by all six algorithms including the Ω shrinkage method and the chi‐square test. Concomitant drugs associated with DDI signal drugs were classified using the DrugBank database to investigate pharmacological properties with a focus on metabolic enzymes and transporters. Results: After the exclusion of established interactions, the analysis identified 107 medications and 49 preferred terms. Analysis at the level of enzymes and transporters indicated that noncanonical pathways exhibited risk intensities, including arylsulfatase A (ARSA, weighted mean Ω = 3.60), macrophage metalloelastase (MMP12, weighted mean Ω = 3.16), organic anion transporting polypeptide 2B1 (OATP2B1, weighted mean Ω = 2.82) and bile salt export pump (BSEP, weighted mean Ω = 2.62). DDI signal drugs associated with high‐intensity targets included acyclovir for duodenal ulcer haemorrhage (Ω = 2.90, 95% CI: 2.12–3.69), mesalazine for an increased tendency to bruise (Ω = 2.96, 95% CI: 1.69–4.22) and digitoxin for haematoma (Ω = 2.65, 95% CI: 1.83–3.46). Interaction signals were also recorded for morphine with injection site haematoma (Ω = 3.05, 95% CI: 1.90–4.21) and eltrombopag with internal haemorrhage (Ω = 3.11, 95% CI: 2.04–4.18). Conclusion: Haemorrhagic risks in apixaban therapy are likely associated with a convergence of transport interference, potential impairment of haemostasis and indirect clinical factors, such as medication‐induced instability. These findings suggest that safety management may extend beyond canonical pathways to consider the possible impact of alternative transporters and functional stability. These results provide a preliminary basis for further clinical validation.
- Open Access
- 17 December 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Left atrial-ventricular coupling index associated with new-onset atrial fibrillation in ST-segment elevation myocardial infarction patients
The management of new-onset atrial fibrillation (NOAF) in ST-segment elevation myocardial infarction (STEMI) patients remains a challenge in clinical. Left
- 17 December 2025
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 26 (1)
Open AccessLeft atrial-ventricular coupling index associated with new-onset atrial fibrillation in ST-segment elevation myocardial infarction patients
The management of new-onset atrial fibrillation (NOAF) in ST-segment elevation myocardial infarction (STEMI) patients remains a challenge in clinical. Left
- 9 May 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (10) , 2041-2051
Prognostic Value of Angiography-Derived Index of Microcirculatory Resistance in Patients with Diabetes and ST-Segment Elevation Myocardial Infarction
- 9 May 2025
- Published by Elsevier in Canadian Journal of Cardiology
- Vol. 41 (10) , 2041-2051
Prognostic Value of Angiography-Derived Index of Microcirculatory Resistance in Patients with Diabetes and ST-Segment Elevation Myocardial Infarction
- Open Access
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1465350
Predictive value of lymphocyte-to-C-reactive protein ratio for left ventricular thrombus in patients with ST-segment elevation myocardial infarction
Background and purpose: Current evidence suggested a correlation between inflammation and Left Ventricular Thrombus (LVT). The lymphocyte to C-reactive protein ratio (LCR) has been established as be a reliable inflammation marker and is associated with the prognosis of patients with ST-segment elevation myocardial infarction (STEMI). However, its relationship with the occurrence of LVT remains unclear. This study aims to evaluate the effectiveness of LCR in predicting LVT in patients with STEMI after undergoing primary percutaneous coronary intervention (pPCI).Methods: A total of 564 STEMI patients who underwent pPCI at the Affiliated Hospital of Xuzhou Medical University from September 2019 to June 2024 were included. Cardiac magnetic resonance imaging (CMR) was used to assess myocardial infarction characteristics and the presence of LVT. The definition of LCR is the lymphocyte to C-reactive protein ratio.Results: Out of 564 patients, 57 were diagnosed with LVT. The median time for CMR testing was 5 (4, 6) days. Univariate regression analysis showed significant differences in left ventricular ejection fraction (LVEF), peak N-terminal pro B-type natriuretic peptide (peak NT-proBNP), peak high-sensitivity troponin T (peak hsTnT), LCR, Late Gadolinium Enhancement% (LGE%), and Microvascular Obstruction% (MVO%) (p < 0.05). Multivariate regression analysis indicated that LCR was an independent predictor for LVT (P = 0.007, OR: 0.001 95% CI: 0.00–0.123). Receiver operating characteristic (ROC) curve analysis showed that LCR has good predictive ability for LVT (Area under the curve: 0.704, p < 0.001). Integration of integral LCR could significantly improve the discrimination and reclassification accuracy for LVT after STEMI (NRI = 0.517, IDI = 0.030; p < 0.001).Conclusion: Lower LCR is independently associated with the risk of LVT in patients with STEMI after pPCI. Integration of LCR can significantly improve the risk model for LVT.
- 24 April 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1465350
Open AccessPredictive value of lymphocyte-to-C-reactive protein ratio for left ventricular thrombus in patients with ST-segment elevation myocardial infarction
Background and purpose: Current evidence suggested a correlation between inflammation and Left Ventricular Thrombus (LVT). The lymphocyte to C-reactive protein ratio (LCR) has been established as be a reliable inflammation marker and is associated with the prognosis of patients with ST-segment elevation myocardial infarction (STEMI). However, its relationship with the occurrence of LVT remains unclear. This study aims to evaluate the effectiveness of LCR in predicting LVT in patients with STEMI after undergoing primary percutaneous coronary intervention (pPCI).Methods: A total of 564 STEMI patients who underwent pPCI at the Affiliated Hospital of Xuzhou Medical University from September 2019 to June 2024 were included. Cardiac magnetic resonance imaging (CMR) was used to assess myocardial infarction characteristics and the presence of LVT. The definition of LCR is the lymphocyte to C-reactive protein ratio.Results: Out of 564 patients, 57 were diagnosed with LVT. The median time for CMR testing was 5 (4, 6) days. Univariate regression analysis showed significant differences in left ventricular ejection fraction (LVEF), peak N-terminal pro B-type natriuretic peptide (peak NT-proBNP), peak high-sensitivity troponin T (peak hsTnT), LCR, Late Gadolinium Enhancement% (LGE%), and Microvascular Obstruction% (MVO%) (p < 0.05). Multivariate regression analysis indicated that LCR was an independent predictor for LVT (P = 0.007, OR: 0.001 95% CI: 0.00–0.123). Receiver operating characteristic (ROC) curve analysis showed that LCR has good predictive ability for LVT (Area under the curve: 0.704, p < 0.001). Integration of integral LCR could significantly improve the discrimination and reclassification accuracy for LVT after STEMI (NRI = 0.517, IDI = 0.030; p < 0.001).Conclusion: Lower LCR is independently associated with the risk of LVT in patients with STEMI after pPCI. Integration of LCR can significantly improve the risk model for LVT.
- Open Access
- 21 April 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31, e947235
Self-Management-Centric Cardiac Rehabilitation for Acute Coronary Syndrome Patients During the COVID-19 Pandemic
BACKGROUND:The COVID-19 pandemic accelerated the adoption of home-based cardiac telerehabilitation (HBCTR), yet evidence on the role of intensified self-management in outcomes for acute coronary syndrome (ACS) patients remains limited. MATERIAL AND METHODS:In this single-center retrospective cohort study (2019-2021), 1627 ACS patients were stratified into 2 groups: those who finished a self-management-centric HBCTR (SMCCRF) plan, and the SMCCR-unfinished (SMCCRNF) group (≥1 missed tele-coaching sessions). The primary outcome was major adverse cardiac events (MACEs); secondary outcomes included self-perceived disease awareness assessed by the Coronary Artery Disease Education Questionnaire-Short Version (CADEQ-SV), behavioral metrics (medication adherence, physical exercise), and risk factor control. Propensity score matching (1: 1, calliper=0.1 standard deviation) generated 619 matched pairs. RESULTS:Over a median follow-up of 23.39 months, the SMCCRF group had lower MACEs rates compared to the SMCCRNF group (7.43% vs 18.74%; HR 0.43, 95% CI 0.30-0.60; P<0.001), with consistent benefits across subgroups. Secondary outcomes favored the SMCCRF group, including higher CADEQ-SV scores at 12 and 36 months (P=0.02), better medication and exercise adherence (both P<0.001), and improved control of blood pressure, low-density lipoprotein cholesterol, and smoking cessation (all P<0.01). However, changes in cardiac function were similar between the 2 groups, and fluctuations of the aforementioned secondary outcomes were observed during long-term follow-up. CONCLUSIONS:SMCCR was associated with reduced cardiovascular risk and enhanced behavioral outcomes in ACS patients during the pandemic, suggesting a dose-dependent relationship between missed sessions and adverse outcomes. The findings support integrating self-management strategies into post-ACS care, pending validation in prospective trials.
- 21 April 2025
- Published by International Scientific Information, Inc. in Medical Science Monitor
- Vol. 31, e947235
Open AccessSelf-Management-Centric Cardiac Rehabilitation for Acute Coronary Syndrome Patients During the COVID-19 Pandemic
BACKGROUND:The COVID-19 pandemic accelerated the adoption of home-based cardiac telerehabilitation (HBCTR), yet evidence on the role of intensified self-management in outcomes for acute coronary syndrome (ACS) patients remains limited. MATERIAL AND METHODS:In this single-center retrospective cohort study (2019-2021), 1627 ACS patients were stratified into 2 groups: those who finished a self-management-centric HBCTR (SMCCRF) plan, and the SMCCR-unfinished (SMCCRNF) group (≥1 missed tele-coaching sessions). The primary outcome was major adverse cardiac events (MACEs); secondary outcomes included self-perceived disease awareness assessed by the Coronary Artery Disease Education Questionnaire-Short Version (CADEQ-SV), behavioral metrics (medication adherence, physical exercise), and risk factor control. Propensity score matching (1: 1, calliper=0.1 standard deviation) generated 619 matched pairs. RESULTS:Over a median follow-up of 23.39 months, the SMCCRF group had lower MACEs rates compared to the SMCCRNF group (7.43% vs 18.74%; HR 0.43, 95% CI 0.30-0.60; P<0.001), with consistent benefits across subgroups. Secondary outcomes favored the SMCCRF group, including higher CADEQ-SV scores at 12 and 36 months (P=0.02), better medication and exercise adherence (both P<0.001), and improved control of blood pressure, low-density lipoprotein cholesterol, and smoking cessation (all P<0.01). However, changes in cardiac function were similar between the 2 groups, and fluctuations of the aforementioned secondary outcomes were observed during long-term follow-up. CONCLUSIONS:SMCCR was associated with reduced cardiovascular risk and enhanced behavioral outcomes in ACS patients during the pandemic, suggesting a dose-dependent relationship between missed sessions and adverse outcomes. The findings support integrating self-management strategies into post-ACS care, pending validation in prospective trials.
- Open Access
- 26 March 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1526057
Role of lymphocyte-to-C-reactive protein ratio in forecasting microvascular obstruction in ST-segment elevation myocardial infarction post-percutaneous coronary intervention
Background: Current research suggests that microvascular obstruction (MVO) following the first percutaneous coronary intervention (PCI) in myocardial infarction patients is closely related to inflammatory responses. The lymphocyte-to-C-reactive protein (CRP) ratio (LCR), as a novel inflammatory marker, is associated with the prognosis of patients with ST-segment elevation myocardial infarction (STEMI). However, the relationship between LCR and MVO remains unclear. This study aims to investigate the correlation between LCR and MVO in STEMI patients undergoing PCI.Methods: This was a single-center retrospective study. We consecutively enrolled STEMI patients who underwent PCI at Xuzhou Medical University Affiliated Hospital, Xuzhou, China, from September 2019 to December 2023. Cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) was used to assess infarct size and the presence of MVO.Results: A total of 551 patients were included in this study, with 267 (48.5%) experiencing MVO. The median time for CMR imaging-based detection of MVO was 5 days (interquartile range: 4, 6). Univariate regression analysis revealed that age, white blood cell count, neutrophil count, left ventricular ejection fraction (LVEF), peak N-terminal pro-B-type natriuretic peptide (NT-proBNP), peak high-sensitivity troponin T (hs-TnT), LCR, LGE percentage (LGE%), and MVO percentage (MVO%) were significantly associated with MVO (p < 0.05). Multivariate regression analysis identified LCR as an independent predictor of MVO [Odds Ratio = 0.18, 95% Confidence Interval (CI): 0.04–0.75, p = 0.019]. Receiver operating characteristic curve analysis demonstrated that LCR had predictive capability for MVO, with a sensitivity of 80.1% and specificity of 45.4% when the LCR value was 0.091 [area under the curve (AUC): 0.654, 95% CI: 0.609–0.700, p < 0.001]. A new predictive model incorporating LCR improved the prediction of MVO occurrence (AUC = 0.815, p < 0.001), with significant differences in net reclassification improvement (p = 0.004) and integrated discrimination improvement (p = 0.023) between the new and old models.Conclusion: A low LCR is an independent risk factor for MVO after PCI in STEMI patients. The predictive model incorporating LCR enhances the ability to predict MVO occurrence in patients with STEMI post-PCI.
- 26 March 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1526057
Open AccessRole of lymphocyte-to-C-reactive protein ratio in forecasting microvascular obstruction in ST-segment elevation myocardial infarction post-percutaneous coronary intervention
Background: Current research suggests that microvascular obstruction (MVO) following the first percutaneous coronary intervention (PCI) in myocardial infarction patients is closely related to inflammatory responses. The lymphocyte-to-C-reactive protein (CRP) ratio (LCR), as a novel inflammatory marker, is associated with the prognosis of patients with ST-segment elevation myocardial infarction (STEMI). However, the relationship between LCR and MVO remains unclear. This study aims to investigate the correlation between LCR and MVO in STEMI patients undergoing PCI.Methods: This was a single-center retrospective study. We consecutively enrolled STEMI patients who underwent PCI at Xuzhou Medical University Affiliated Hospital, Xuzhou, China, from September 2019 to December 2023. Cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) was used to assess infarct size and the presence of MVO.Results: A total of 551 patients were included in this study, with 267 (48.5%) experiencing MVO. The median time for CMR imaging-based detection of MVO was 5 days (interquartile range: 4, 6). Univariate regression analysis revealed that age, white blood cell count, neutrophil count, left ventricular ejection fraction (LVEF), peak N-terminal pro-B-type natriuretic peptide (NT-proBNP), peak high-sensitivity troponin T (hs-TnT), LCR, LGE percentage (LGE%), and MVO percentage (MVO%) were significantly associated with MVO (p < 0.05). Multivariate regression analysis identified LCR as an independent predictor of MVO [Odds Ratio = 0.18, 95% Confidence Interval (CI): 0.04–0.75, p = 0.019]. Receiver operating characteristic curve analysis demonstrated that LCR had predictive capability for MVO, with a sensitivity of 80.1% and specificity of 45.4% when the LCR value was 0.091 [area under the curve (AUC): 0.654, 95% CI: 0.609–0.700, p < 0.001]. A new predictive model incorporating LCR improved the prediction of MVO occurrence (AUC = 0.815, p < 0.001), with significant differences in net reclassification improvement (p = 0.004) and integrated discrimination improvement (p = 0.023) between the new and old models.Conclusion: A low LCR is an independent risk factor for MVO after PCI in STEMI patients. The predictive model incorporating LCR enhances the ability to predict MVO occurrence in patients with STEMI post-PCI.